Social Post
Tap into a New Possibility for Adolescent Depression!
Introducing NeuroStar TMS, a NEW FDA-cleared first-line, add-on therapy for adolescents aged 15 and older.
Available for posting until June 30, 2026
Facebook
Tap into a New Possibility for Adolescent Depression!
Introducing NeuroStar TMS, a NEW FDA-cleared first-line, add-on therapy for adolescents aged 15 and older.
Proven safe and effective for adolescents! In a clinical study of 1,169 adolescent patients:
78% cited improvement in their depression symptoms*
48% showed symptom relief (remission)*
Call our practice today to learn more about NeuroStar TMS for depression!
Visit neurostar.com for full safety and prescribing information.
*FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.
#NeuroStarProvider
#NeuroStarConnects
#NeuroStar
#NeuroStarSocial
Available for posting until June 30, 2026
Instagram Business
Tap into a New Possibility for Adolescent Depression!
Introducing NeuroStar TMS, a NEW FDA-cleared first-line, add-on therapy for adolescents aged 15 and older.
Proven safe and effective for adolescents! In a clinical study of 1,169 adolescent patients:
78% cited improvement in their depression symptoms*
48% showed symptom relief (remission)*
Call our practice today to learn more about NeuroStar TMS for depression!
Visit neurostar.com for full safety and prescribing information.
*FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.
#NeuroStarProvider
#NeuroStarConnects
#NeuroStar
#NeuroStarSocial
Available for posting until June 30, 2026
Facebook
Tap into a New Possibility for Adolescent Depression!
Introducing NeuroStar TMS, a NEW FDA-cleared first-line, add-on therapy for adolescents aged 15 and older.
Proven safe and effective for adolescents! In a clinical study of 1,169 adolescent patients:
78% cited improvement in their depression symptoms*
48% showed symptom relief (remission)*
Call our practice today to learn more about NeuroStar TMS for depression!
Visit neurostar.com for full safety and prescribing information.
*FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.
#NeuroStarProvider
#NeuroStarConnects
#NeuroStar
#NeuroStarSocial
Available for posting until June 30, 2026
Instagram Business
Tap into a New Possibility for Adolescent Depression!
Introducing NeuroStar TMS, a NEW FDA-cleared first-line, add-on therapy for adolescents aged 15 and older.
Proven safe and effective for adolescents! In a clinical study of 1,169 adolescent patients:
78% cited improvement in their depression symptoms*
48% showed symptom relief (remission)*
Call our practice today to learn more about NeuroStar TMS for depression!
Visit neurostar.com for full safety and prescribing information.
*FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.
#NeuroStarProvider
#NeuroStarConnects
#NeuroStar
#NeuroStarSocial